Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S42-9. doi: 10.1016/j.ijrobp.2009.04.095.
Dose-volume data for myelopathy in humans treated with radiotherapy (RT) to the spine is reviewed, along with pertinent preclinical data. Using conventional fractionation of 1.8-2 Gy/fraction to the full-thickness cord, the estimated risk of myelopathy is <1% and <10% at 54 Gy and 61 Gy, respectively, with a calculated strong dependence on dose/fraction (alpha/beta = 0.87 Gy.) Reirradiation data in animals and humans suggest partial repair of RT-induced subclinical damage becoming evident about 6 months post-RT and increasing over the next 2 years. Reports of myelopathy from stereotactic radiosurgery to spinal lesions appear rare (<1%) when the maximum spinal cord dose is limited to the equivalent of 13 Gy in a single fraction or 20 Gy in three fractions. However, long-term data are insufficient to calculate a dose-volume relationship for myelopathy when the partial cord is treated with a hypofractionated regimen.
本文回顾了接受脊柱放疗(RT)治疗的患者发生脊髓病的剂量-体积数据,并结合了相关的临床前数据。对于全脊髓厚度采用 1.8-2 Gy/分次的常规分割,估计脊髓病的风险分别为<1%和<10%,在 54 Gy 和 61 Gy 时,剂量/分次依赖性强(α/β=0.87 Gy)。动物和人类的再放疗数据表明,RT 诱导的亚临床损伤在 RT 后约 6 个月开始出现部分修复,并在接下来的 2 年内逐渐增加。当最大脊髓剂量限制在单次分割 13 Gy 或三次分割 20 Gy 时,立体定向放射外科治疗脊柱病变的脊髓病报告罕见(<1%)。然而,当采用低分割方案治疗部分脊髓时,脊髓病的剂量-体积关系的长期数据不足,无法计算。